Takeda Pharmaceutical Ceases Diabetes Therapy Development (Japan)
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical in Japan has ceased development of diabetes therapy combining Actos with TAX-536, an angiotensin receptor blocker, because they do not mix well. (Click here for more